Nebivolol Medreg (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractility. It also stimulates nitric oxide release from the endothelium, causing vasodilation and further lowering systemic vascular resistance.

The specific dose of Nebivolol Medreg is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the dose prescribed by their healthcare professional.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilatory properties, which may result in fewer metabolic side effects compared with non‑selective beta blockers. It is often chosen for patients who need both heart‑rate control and improved vascular tone.

Nebivolol Medreg should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and store it out of reach of children.

Nebivolol Medreg is taken orally, usually once daily with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water.

Serious risks include severe bradycardia, marked hypotension, heart block, and bronchospasm in patients with underlying respiratory disease. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, difficulty breathing, or severe dizziness.

Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, second‑ or third‑degree atrioventricular block, or uncontrolled heart failure. It should also be used with caution in individuals with asthma, COPD, or severe liver impairment.